1-3 of 3
Kenneth Kopecky, PhD
Close
Sort by
Journal Articles

Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.

Pamela S. Becker, MD, PhD, Sylvia Chien, Mikhail Roshal, MD, PhD, Brent Wood, MD, PhD, Elihu Estey, MD, Thalia Papayannopoulou, MD, Xin Zhao, MD, Soumit Basu, MD, PhD, Mark McGrath, Kenneth Kopecky, PhD, Frederick R Appelbaum, MD
Journal: Blood
Blood (2009) 114 (22): 2658.
https://doi.org/10.1182/blood.V114.22.2658.2658
Published: 2009
Journal Articles

Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.

Stephen Petersdorf, MD, Kenneth Kopecky, PhD, Robert K Stuart, MD, Richard A. Larson, MD, Thomas J. Nevill, MD, FRCPC, Leif Stenke, MD, PhD, Marilyn L. Slovak, PhD, Martin S. Tallman, MD, Cheryl L. Willman, MD, Harry Erba, MD, Frederick R Appelbaum
Journal: Blood
Blood (2009) 114 (22): 790.
https://doi.org/10.1182/blood.V114.22.790.790
Published: 2009
Journal Articles

XPD DNA Nucleotide Excision Repair (NER) Gene Polymorphisms Associated with DNA Repair Deficiency May Predict Better Treatment Outcomes in Secondary Acute Myeloid Leukemia (AML).

Nataliya Kuptsova-Clarkson, PhD, Christine Ambrosone, PhD, Joli Weiss, PhD, Maria R. Baer, MD, Lara Sucheston, PhD, Gary Zirpoli, PhD, Kenneth Kopecky, PhD, Laurie Ann Ford, Javier Blanco, PhD, Meir Wetzler, MD, Kirsten Moysich, PhD
Journal: Blood
Blood (2009) 114 (22): 168.
https://doi.org/10.1182/blood.V114.22.168.168
Published: 2009